CSL Limited (CSL) — 62/100 Investor Analysis
CSL Limited faces a critical juncture as it navigates a leadership change, a class action lawsuit, and the integration of its Vifor acquisition, resulting in a cautious HOLD rating despite its strong underlying plasma business.
CSL Limited: Navigating a Period of Strategic Transition
CSL Limited (ASX:CSL) is currently undergoing a significant leadership and operational reset. With the appointment of Deborah Waterhouse as CEO and a focus on stabilizing the CSL Vifor and Seqirus divisions, the company is attempting to move past a turbulent FY2026.
Financial Performance and Outlook
The company reported FY2026 underlying NPATA of US$3.1 billion, though reported NPAT suffered a significant loss of US$2.6 billion. While cash flow from operations remains robust at US$3.5 billion, the market is cautious regarding the impact of generic competition on the Vifor portfolio and the ongoing class action litigation regarding disclosure practices.
Strategic Developments
CSL has recently entered a major US$1.6 billion partnership with Alentis Therapeutics to develop lixudebart, signaling a continued commitment to high-value R&D. However, the stock remains under pressure from a class action lawsuit filed in the Supreme Court of Victoria, which alleges breaches of continuous disclosure obligations between 2025 and 2026.
Investment Thesis
The core plasma business remains a strong moat, but the company's valuation is currently constrained by execution risks and legal uncertainty. Investors should look for signs of margin expansion and successful integration of new pipeline assets before increasing exposure.